Evenamide

Evenamide (NW-3509) is an orally available voltage-gated sodium channel (VGSC) blocker (Ki=0.4 μM) for the research of schizophrenia. Evenamide shows efficacy in a broad spectrum of rodent models of psychosis, mania, depression, and aggressiveness[1][2].

Product Specifications

CAS Number

[1092977-61-1]

Product Name Alternative

NW-3509

UNSPSC

12352005

Target

Sodium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/evenamide.html

Purity

96.45

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N(C)C)CNCCC1=CC=CC(OCCCC)=C1

Molecular Formula

C16H26N2O2

Molecular Weight

278.39

References & Citations

[1]Valentina Zuliani, et al. Advances in Design and Development of Sodium Channel Blockers. Ion Channels and Their Inhibitors pp 79-115.|[2]Faravelli, et al. P.3.f.022 Evenamide (formerly NW-3509) targets new mechanisms, and represents a new approach to the management of untreated symptoms in schizophrenia.